38790979|t|Inhibition of NF-kappaB with an Analog of Withaferin-A Restores TDP-43 Homeostasis and Proteome Profiles in a Model of Sporadic ALS.
38790979|a|The current knowledge on pathogenic mechanisms in amyotrophic lateral sclerosis (ALS) has widely been derived from studies with cell and animal models bearing ALS-linked genetic mutations. However, it remains unclear to what extent these disease models are of relevance to sporadic ALS. Few years ago, we reported that the cerebrospinal fluid (CSF) from sporadic ALS patients contains toxic factors for disease transmission in mice via chronic intracerebroventricular (i.c.v.) infusion. Thus a 14-day i.c.v. infusion of pooled CSF samples from ALS cases in mice provoked motor impairment as well as ALS-like pathological features. This offers a unique paradigm to test therapeutics in the context of sporadic ALS disease. Here, we tested a new Withaferin-A analog (IMS-088) inhibitor of NF-kappaB that was found recently to mitigate disease phenotypes in mouse models of familial disease expressing TDP-43 mutant. Our results show that oral intake of IMS-088 ameliorated motor performance of mice infused with ALS-CSF and it alleviated pathological changes including TDP-43 proteinopathy, neurofilament disorganization, and neuroinflammation. Moreover, CSF infusion experiments were carried out with transgenic mice having neuronal expression of tagged ribosomal protein (hNfL-RFP mice), which allowed immunoprecipitation of neuronal ribosomes for analysis by mass spectrometry of the translational peptide signatures. The results indicate that treatment with IMS-088 prevented many proteomic alterations associated with exposure to ALS-CSF involving pathways related to cytoskeletal changes, inflammation, metabolic dysfunction, mitochondria, UPS, and autophagy dysfunction. The effective disease-modifying effects of this drug in a mouse model based on i.c.v. infusion of ALS-CSF suggest that the NF-kappaB signaling pathway represents a compelling therapeutic target for sporadic ALS.
38790979	14	23	NF-kappaB	Gene	18033
38790979	42	54	Withaferin-A	Chemical	MESH:C009684
38790979	64	70	TDP-43	Gene	230908
38790979	119	131	Sporadic ALS	Disease	MESH:C531617
38790979	183	212	amyotrophic lateral sclerosis	Disease	MESH:D000690
38790979	214	217	ALS	Disease	MESH:D000690
38790979	292	295	ALS	Disease	MESH:D000690
38790979	406	418	sporadic ALS	Disease	MESH:C531617
38790979	487	499	sporadic ALS	Disease	MESH:C531617
38790979	500	508	patients	Species	9606
38790979	560	564	mice	Species	10090
38790979	677	680	ALS	Disease	MESH:D000690
38790979	690	694	mice	Species	10090
38790979	704	720	motor impairment	Disease	MESH:D000068079
38790979	732	735	ALS	Disease	MESH:D000690
38790979	833	845	sporadic ALS	Disease	MESH:C531617
38790979	877	889	Withaferin-A	Chemical	MESH:C009684
38790979	898	905	IMS-088	Chemical	-
38790979	920	929	NF-kappaB	Gene	18033
38790979	988	993	mouse	Species	10090
38790979	1004	1020	familial disease	Disease	MESH:D057180
38790979	1032	1038	TDP-43	Gene	230908
38790979	1084	1091	IMS-088	Chemical	-
38790979	1125	1129	mice	Species	10090
38790979	1200	1220	TDP-43 proteinopathy	Disease	MESH:D057177
38790979	1257	1274	neuroinflammation	Disease	MESH:D000090862
38790979	1344	1348	mice	Species	10090
38790979	1414	1418	mice	Species	10090
38790979	1593	1600	IMS-088	Chemical	-
38790979	1666	1673	ALS-CSF	Disease	MESH:D000690
38790979	1726	1738	inflammation	Disease	MESH:D007249
38790979	1740	1761	metabolic dysfunction	Disease	MESH:D008659
38790979	1867	1872	mouse	Species	10090
38790979	1907	1914	ALS-CSF	Disease	MESH:D000690
38790979	1932	1941	NF-kappaB	Gene	18033
38790979	2007	2019	sporadic ALS	Disease	MESH:C531617
38790979	Association	MESH:C531617	18033
38790979	Negative_Correlation	MESH:C009684	18033
38790979	Association	MESH:D057180	230908
38790979	Association	MESH:C531617	230908
38790979	Association	MESH:D000690	18033
38790979	Association	18033	230908
38790979	Negative_Correlation	MESH:C009684	230908

